Skip to main content
logo
Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.97
-0.10 (-0.99%)
Jul 29, 2026, 4:00 PM EDT - Market closed

Keros Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
33.18244.063.550.15-20.1
Revenue Growth
-84.55%6774.96%2250.99%---
Gross Profit
33.18244.063.550.15-20.1
Operating Income
-81.0867.57-210.83-169.94-114.79-56.37
Net Income
-61.4487.01-187.35-152.99-104.68-58.74
Earnings Per Share
-3.012.30-5.00-5.20-4.15-2.52
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
281.5287.42559.93331.15279.05230.04
Total Debt
16.3116.8818.8614.4413.271.09
Net Cash (Debt)
265.19270.53541.07316.7265.78228.95
Net Cash Growth
-62.23%-50.00%70.84%19.16%16.09%-13.60%
Net Cash Per Share
8.287.1514.4510.7510.539.81

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-57.2107.51-160.87-124.51-70.06-62.15
Capital Expenditures
-1.06-1.55-1.93-2.46-1.24-1.02
Free Cash Flow
-58.25105.95-162.8-126.97-71.3-63.17
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%-100.00%
Operating Margin
-244.34%27.69%-5938.96%-112544.00%--280.46%
Pretax Margin
-125.44%37.65%-5269.10%-101319.21%--282.25%
Profit Margin
-114.45%35.65%-5277.55%-101319.00%--292.26%
FCF Margin
-175.56%43.41%-4585.92%-84087.40%--314.29%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-8.85----
P/FCF Ratio
-3.76----
PS Ratio
5.931.63180.848384.12-69.79